Aptorum Group Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APM research report →
Price Chart
About the company
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections.
- CEO
- Ian Huen
- IPO
- 2018
- Employees
- 2
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on APM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.24M
- P/E
- -0.26
- Fwd P/E
- 2.66
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.02
- EV/EBITDA
- -0.22
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -5.94%
- ROIC
- -2.30%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-1,817,528
- Net Income
- $-1,363,270+68.1%
- EPS
- $-1.90+75.6%
- OCF Growth
- -54.1%
- FCF Growth
- -54.1%
- 52W High
- $44.70
- 52W Low
- $0.60
- 50D MA
- $8.64
- 200D MA
- $10.12
- Beta
- 0.17
- RSI (14)
- 56
- Avg Volume
- 34.12K
No earnings-call transcripts are available for APM yet.
- Free Float
- 84.4%
- Shares Outstanding
- 634.68K
- Float Shares
- 535.93K
of shares held by institutions
8 13F filers
Our APM coverage
Recent articles, reports, and earnings notes.
No research on APM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APM report →Woodside Energy Half-Year Report for Period Ended 30 June 2026
gurufocus.com · Aug 25
MHI Receives Contract for APM System at Dubai's Al Maktoum International Airport
gurufocus.com · Aug 21
Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Amid Tariff Pressures
gurufocus.com · Aug 7
Aptorum Group Provides Update on DiamiR Biosciences Merger
globenewswire.com · Jul 16
Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer's Association International Conference
globenewswire.com · Jul 8
Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer's Disease Biomarkers
globenewswire.com · Jun 22
Statement in Response to Silver Elephant's News Release Dated June 17, 2026
newsfilecorp.com · Jun 18
Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences
globenewswire.com · Jun 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.